For clinics, med spas and telehealth. And everyone in peptides and longevity.

Wednesday, Nov. 4, 2026

Grindr pays $250M for Freddie, a PrEP telehealth

Also in this issue: Bios hits four U.S. clinic deals in four months

Forwarded this? Get it weekday mornings.

Take. Apps with big audiences will pay real money for a telehealth that already has prescribers and a pharmacy behind it. Expect more of them to shop. A single-service clinic with a working pharmacy setup has a buyer it didn't have a year ago. We'd get the books and pharmacy contracts in order now.

Grindr closed its purchase of PurposeMed, the parent of Freddie, on Monday. Freddie runs PrEP and HIV-prevention care by telehealth in the U.S. and Canada. Grindr paid $190M in cash plus $60M in stock. Sellers are eligible for up to $70M more in cash if the business hits 2027 targets, paid in 2028.

CEO George Arison said the deal buys "a profitable business" with "clinical and pharmacy capabilities that would take us at least two years to build ourselves." Grindr users now reach Freddie from a Health tab inside the app.

The SEC filing puts the stock portion at 3,851,684 Grindr shares. The price is subject to customary adjustments. Grindr disclosed no revenue or patient count for Freddie, so there is no multiple to quote.

Money

Bios Wellness reaches four U.S. clinic deals in four months

Sheppard, the Canadian buyer's U.S. counsel, says it advised Bios on Sonata Aesthetics in Denver plus Dr. Shel Wellness & Aesthetics and Elite Doc Health & Beauty in Houston. Gleam Medical Spa in Denver came first, in July. That makes Elite Doc the fourth deal and Bios' second Houston clinic. Tuesday's issue called Dr. Shel the third deal, using the seller's advisor's count. No prices were disclosed.

Bios is building two clusters, so expect it to keep calling Denver and Houston owners. Wellness and hormone clinics in those metros should get a valuation before that call comes.

The Signal

Telehealth

FDA warns RonanRx over compounded GLP-1 claims

FDA sent RonanRx a warning letter dated Oct. 30 after reviewing its website and X account in September. The letter says the vials pictured carry the RonanRx name, suggesting RonanRx compounds the drugs when it doesn't. FDA also objects to a site heading reading "FDA-Approved Compounded Medications" and an X bio saying "Explore GLP-1s like Ozempic." A pinned video called the products "American made" and "farm-to-table drugs." FDA says its records list no U.S. maker of semaglutide or tirzepatide ingredient for compounding. These are FDA's allegations. RonanRx has 15 working days to respond. Disclaimers on the page didn't save it, per the letter.

503A/503B

Ozari Health names the pharmacies that fill its GLP-1s

Ozari Health, a compounded GLP-1 telehealth, now routes prescriptions to five named 503A sterile pharmacies in Florida and Texas, per its GlobeNewswire release. Every label names the pharmacy that made the vial. Its cheapest tirzepatide plan is $125 a month billed quarterly, with no membership fee, the company says. Patients will start asking every clinic who fills their vial.

Patient Demand

Eden advertises $99 compounded semaglutide with no membership fee

Eden's weight-loss page lists compounded semaglutide at $99 a month and tirzepatide at $129, as "one clear, all-inclusive price." Its FAQ on that page says there is no separate membership fee. Eden's terms of service still describe an Eden Membership and say medication costs are "separate from and in addition to the membership fee." Clinics that add a membership on top of the drug price should expect patients to ask about the gap.

Prescriber

FDA updates labels on three more estradiol patches

FDA approved new labeling Oct. 30 for Minivelle, Vivelle and Vivelle-Dot, per its updated product list. The labels drop boxed-warning language on heart disease, breast cancer and dementia. HHS says patch output has doubled in 12 months. HHS adds that FDA sees no imminent nationwide shortage. Expect more women asking about patches in places where pharmacies still can't stock them.

Operator Q&A

TRT Nation patients say it is leaving Missouri and Indiana

Two patients posted on Reddit (r/trt, r/Testosterone) on Monday that TRT Nation emailed them about state exits. One says Missouri service ends after Jan. 31, 2027. We haven't seen the email. Licensed clinics in both states may get calls from men who need a new prescriber and labs.

Wire

  • JECT, a New York injectables brand, leased 24 Taylor Place in downtown Westport for its first Connecticut med spa, per the landlord's broker, Saugatuck Commercial Real Estate.
  • Hims & Hers reports third-quarter results Monday, Nov. 9, after the close.

Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.